MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.140
+0.050
+4.59%
After Hours: 1.141 +0.001 +0.07% 18:17 02/06 EST
OPEN
1.120
PREV CLOSE
1.090
HIGH
1.190
LOW
1.105
VOLUME
715.04K
TURNOVER
--
52 WEEK HIGH
12.88
52 WEEK LOW
1.090
MARKET CAP
70.05M
P/E (TTM)
-0.3974
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (0126-0130)?
Weekly Report · 4d ago
Pliant Therapeutics Unveils Data on Oral Integrin Inhibitor for ICI-Resistant Tumors
Reuters · 01/27 15:38
Weekly Report: what happened at PLRX last week (0119-0123)?
Weekly Report · 01/26 10:15
Weekly Report: what happened at PLRX last week (0112-0116)?
Weekly Report · 01/19 10:21
Weekly Report: what happened at PLRX last week (0105-0109)?
Weekly Report · 01/12 10:20
Weekly Report: what happened at PLRX last week (1229-0102)?
Weekly Report · 01/05 10:14
Weekly Report: what happened at PLRX last week (1222-1226)?
Weekly Report · 12/29/2025 10:14
Pliant Therapeutics Files Initial Beneficial Ownership Statement for Chief Operating Officer Minnie Kuo
Reuters · 12/22/2025 22:03
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.